Plasma concentration of urotensin II is raised in hypertension

被引:156
作者
Cheung, BMY [1 ]
Leung, R [1 ]
Man, YB [1 ]
Wong, LYF [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Cheung Dept Med, Pokfulam, Peoples R China
关键词
hypertension; radioimmunoassay; urotensin; vasoactive peptides; vasoconstriction;
D O I
10.1097/01.hjh.0000125452.28861.f1
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objectives Urotensin II is the most potent vasoconstrictor known. Its role in hypertension has not been investigated. Here, we studied the plasma levels in hypertensive and normotensive human subjects. Design A cross-sectional case-control study. Setting Hypertension clinic and research clinic of a university teaching hospital. Participants Sixty-two hypertensive outpatient subjects (52% male, aged 57 +/- 13 years) and 62 normotensive controls (45% male, aged 54 +/- 13 years) recruited from the general population. Main outcome measures Plasma urotensin II levels measured by radioimmunoassay, systolic and diastolic blood pressure. Results Plasma urotensin II was 8.8 +/- 0.9 pmol/l in normotensive controls and 13.6 +/- 1.4 pmol/l in hypertensive subjects (P = 0.005). In multiple regression analysis, systolic blood pressure was related to plasma urotensin II (P = 0.31, P < 0.001) and age (P = 0.28, P = 0.001), accounting for 10 and 8%, respectively, of the variance in systolic blood pressure. There was no significant correlation with gender, renal function or diabetes. Conclusions Plasma urotensin II was raised in hypertensive patients compared to normotensive controls, and was directly related to systolic blood pressure. Our findings raise the possibility that urotensin II may have an aetiological role in hypertension and its complications.
引用
收藏
页码:1341 / 1344
页数:4
相关论文
共 15 条
[1]   Urotensin II: a new mediator in cardiopulmonary regulation? [J].
Affolter, J ;
Webb, DJ .
LANCET, 2001, 358 (9284) :774-775
[2]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[3]  
Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533
[4]   Diastolic blood pressure is related to urinary sodium excretion in hypertensive Chinese patients [J].
Cheung, BMY ;
Ho, SPC ;
Cheung, AHK ;
Lau, CP .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2000, 93 (03) :163-168
[5]   Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension [J].
Heller, J ;
Schepke, M ;
Neef, M ;
Woitas, R ;
Rabe, C ;
Sauerbruch, T .
JOURNAL OF HEPATOLOGY, 2002, 37 (06) :767-772
[6]   The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese [J].
Janus, ED ;
Wat, NMS ;
Lam, KSL ;
Cockram, CS ;
Siu, STS ;
Liu, LJ ;
Lam, TH .
DIABETIC MEDICINE, 2000, 17 (10) :741-745
[7]   Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1 [J].
Maguire, JJ ;
Kuc, RE ;
Davenport, AP .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (03) :441-446
[8]   Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues [J].
Matsushita, M ;
Shichiri, M ;
Imai, T ;
Iwashina, M ;
Tanaka, H ;
Takasu, N ;
Hirata, Y .
JOURNAL OF HYPERTENSION, 2001, 19 (12) :2185-2190
[9]   Plasma urotensin in human systolic heart failure [J].
Ng, LL ;
Loke, I ;
O'Brien, RJ ;
Squire, LB ;
Davies, JE .
CIRCULATION, 2002, 106 (23) :2877-2880
[10]  
Richards AM, 2002, LANCET, V360, P545